XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Stock Option Activities
Following is a summary of stock option activities for the nine months ended September 30, 2023:
OptionsWeighted
Average
Exercise Price
Weighted
Average
Grant Date
Fair Value
Weighted
Average
Remaining
Life
(years)
Intrinsic
Value
Outstanding – January 1, 20237,603,864 $0.19 $0.21 4.6$25,795 
Granted— — — 
Exercised(348,013)0.18 0.23 
Forfeited— — — 
Outstanding – September 30, 2023
7,255,851 $0.19 $0.21 3.8$17,429 
Exercisable as of September 30, 2023
7,255,851 $0.19 $0.21 3.8$17,429 
Summary of Restricted Stock Activity

Restricted Stock Units
Weighted Average Grant Date
Fair Value
Non-vested – January 1, 20237,466,636 $5.52 
Granted
675,293 3.55 
Vested
(1,830,986)6.31 
Forfeited
(202,145)6.03 
Non-vested – September 30, 2023
6,108,798 $5.05 
Summary of Stock-based Compensation Expense
Stock-based compensation expense for stock options and restricted stock units in the unaudited interim condensed consolidated statements of operations is summarized as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
2023202220232022
Software development
$147 $189 $608 $718 
General and administrative(1)
2,903 1,439 7,915 4,657 
Selling and marketing
280 57486 252
Total stock-based compensation expense
$3,330 $1,685 $9,009 $5,627 
________
(1) For the nine months ended September 30, 2023, the Company included a credit of $339 in connection with the settlement of the equity-based portion of contingent consideration related to the acquisition of Trinity Air Medical, Inc. that was paid in the first quarter of 2023 in respect of 2022 results.